Showing 4901-4910 of 6036 results for "".
- LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-presents-valeda-treatment-benefits-for-photobiomodulation-in-early-patients-with-diabetic-retinopathy-and-macular-edema/2479177/LumiThera announced research investigators presented positive clinical findings following PBM treatment with the Valeda Light Delivery System from an ongoing safety and efficacy study in early diabetic retinopathy (DR) patients with central macular edema (DME) at the Association for Research in V
- Gyroscope Therapeutics Postpones Initial Public Offeringhttps://modernod.com/news/gyroscope-therapeutics-postpones-initial-public-offering/2479176/Gyroscope Therapeutics announced it has postponed plans for its initial public offering. “In light of market conditions, we have decided to postpone our planned initial public offering,” Khurem Farooq, Chief Executive Officer, said in a company news release. “Based on the
- Melling Medical to Distribute Optos Technology to Federal Health Facilitieshttps://modernod.com/news/melling-medical-to-distribute-optos-technology-to-federal-health-facilities/2479175/MellingMedical today announced a new distribution agreement with Optos Inc. to deliver their state-of-the-art equipment to facilities across the federal health care system. “As they work to accommodate growing caseloads, doctors in the federal health system are looking for t
- ProQR Therapeutics and Yarrow Biotechnology Announce Exclusive License and Discovery Collaboration for Undisclosed Ophthalmic Targethttps://modernod.com/news/proqr-therapeutics-and-yarrow-biotechnology-announce-exclusive-license-and-discovery-collaboration-for-undisclosed-ophthalmic-target/2479165/RTW Investments and ProQR Therapeutics announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide technology (ASO) to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Yarrow is f
- Oculis Announces Financing to Advance Topical Therapies for Posterior and Anterior Segmentshttps://modernod.com/news/oculis-announces-financing-to-advance-therapies-for-anterior-segment/2479162/Oculis announced that it has closed an oversubscribed $57 million Series C financing. Proceeds from this financing will accelerate Oculis’ strategy with the aim of delivering key goals in the near-term to drive shareholder value and bring transformative therapies to patients. The
- jCyte Identifies Predictive Biomarker for jCell Therapy in Largest Phase 3 Study for Retinitis Pigmentosahttps://modernod.com/news/jcyte-identifies-predictive-biomarker-for-jcell-therapy-in-largest-phase-3-study-for-retinitis-pigmentosa/2479157/jCyte announced presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, identifying a predictive biomarker for the upcoming phase 3 study for jCell therapy in retinitis pigmentosa. A detailed analysis by the Cleveland Clinic Cole Eye Institute
- Alcon Presents Highlights of ARVO 2021 Datahttps://modernod.com/news/alcon-presents-highlights-of-arvo-2021-data/2479149/Alcon will be presenting new data at the Association for Research in Vision and Ophthalmology (ARVO) Virtual Meeting (May 1-7). Presentations include data for the Systane iLux MGD Thermal Pulsation System, Precision1 daily disposable contact lenses, and a forthcoming reusable monthly contact lens
- The Countess of Wessex Praises Work of Sight-Saving Charity Orbis During Pandemichttps://modernod.com/news/the-countess-of-wessex-praises-work-of-sight-saving-charity-orbis-during-pandemic/2479147/On April 28, 2021, Her Royal Highness The Countess of Wessex spoke in support of international eye care charity Orbis, at a virtual event to discuss delivering eye care to those most in need during the COVID-19 outbreak.
- Oxurion NV Presenting Scientific Data at ARVO 2021 Annual Meetinghttps://modernod.com/news/oxurion-nv-presenting-scientific-data-at-arvo-2021-annual-meeting/2479144/Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021. The details of the presentation are as follows: Title: The Mouse Sodium Iodate Mo
- Alcon to Acquire US Commercialization Rights to Glaucoma Eye Drop Simbrinzahttps://modernod.com/news/alcon-to-acquire-us-commercialization-rights-to-ophthalmic-eye-drop-simbrinza/2479138/Alcon announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Under terms of the deal, Alcon will pay $355 million at closing, which is expected to occur in the sec